Eledon Pharmaceuticals Business Summary

Eledon Pharmaceuticals, Inc. (ELDN) is a clinical-stage biotechnology company primarily focused on developing immune-modulating therapies for organ and cellular transplantation and autoimmune diseases. The company currently generates no product revenue, operating instead through capital raises, such as its $57.5 million financing in late 2025, and potential future licensing or milestone-based partnerships. Its business segments are defined by its clinical development programs for its lead asset, tegoprubart, a high-affinity anti-CD40L antibody. These segments include kidney allotransplantation (Phase 3 ready), islet cell transplantation for Type 1 diabetes, and xenotransplantation (pig-to-human). Eledon competes directly with companies such as Altimmune, Inc., Gossamer Bio, and Keros Therapeutics. Within this landscape, Eledon differentiates itself by targeting the CD40L pathway to provide a non-lymphocyte depleting, safer alternative to the current standard-of-care calcineurin inhibitors, like tacrolimus, which are often associated with significant long-term toxicities. The leadership team is anchored by Chief Executive Officer David-Alexandre C. Gros, M.D., who previously held senior roles at Sanofi, Alnylam Pharmaceuticals, and Neurocrine Biosciences. President and Chief Scientific Officer Steven N. Perrin, Ph.D., joined through the 2020 acquisition of Anelixis Therapeutics, where he was the founder and CEO, bringing over two decades of R&D experience from Biogen and the ALS Therapy Development Institute. The executive suite also includes Chief Financial Officer Paul Little, formerly of Sancilio & Company, and Chief Medical Officer Eliezer Katz, M.D., who joined in late 2023 from eGenesis and has a deep background in transplant surgery and clinical development. The company is supported by a board chaired by Keith Katkin and backed by notable institutional investors including BVF Partners L.P., RA Capital Management, BlackRock, and Vanguard.